The medical letter issue 1137
Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication
TESTS FOR DRUGS OF ABUSE
Testing for drug use has become increasingly common, not only in health care, but also
in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal jus-
Performance-enhancing drugs such as anabolic steroids, growth hormone
, and others) and erythropoietin (Procrit, Epogen)
are not discussed here.
Assays can be categorized as preliminary (initial) or confirmatory tests. Prel-
iminary tests include immunological assays such as radioimmunoassay (RIA), homogenous
enzyme immunoassay (EMIT), fluorescence polarization immunoassay (FPIA) and enzyme-
linked immunoassay (ELISA). These assays tend to be highly sensitive, but they may be less
specific than confirmatory tests. Confirmatory tests include high performance liquid chroma-
tography (HPLC) gas chromatography and mass spectrometry; a combination of chromatogra-
phy and mass spectrometry is considered the "gold standard" for confirmatory testing.
is used most often to test for drugs because it is obtained easily and
concentrations of drugs in urine are relatively high
Ingesting large quantities of liquids, taking diuretics or adding water or household bleach to a
urine specimen can mask illicit drug use. Blood
is useful for quantitative determinations, but
many abused substances leave the blood relatively quickly. Where there is a well-accepted
relationship between blood concentrations and pharmacological effect, as with ethanol, blood
testing can be helpful. Saliva
may be particularly useful for assessing drugs taken too recent-
ly to be detectable in urine. Testing procedures may affect saliva concentrations; saliva is
usually slightly more acidic than plasma, but when stimulated to collect sufficient volume for
a sample, it may become more basic, which can alter the saliva-to-plasma (S/P) ratio. Smok-
ing or eating can contaminate a saliva sample. Breath
testing is useful for volatile sub-
stances, especially alcohol, because urine alcohol levels do not correlate well with blood al-
cohol levels, while breath alcohol does. Sweat
patches worn for 7 days have been used to
monitor patients in the criminal justice system or in drug treatment facilities. Environmental
contamination can lead to false-positive results
gives a better long-term measure (1-6 months) of substance abuse than
urine because drugs stored in hair remain there as the hair grows out. The concentration of
drugs in hair varies with hair color, hair structure and growth rates. Shampoos, bleaches or
dyes can alter drug concentrations in hair. Volatile drugs like marijuana may adhere to hair
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti, M.D., M.P.H.,
Weill Medical College of Cornell University
CONSULTING EDITOR: Martin A. Rizack, M.D., Ph.D.,
Rockefeller University ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard ASSISTANT EDITOR: Susie Wong
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D.,
University of Washington; Neal H. Steigbigel, M.D.,
New York University School of Medicine
ADVISORY BOARD: William T. Beaver, M.D.,
Georgetown University School of Medicine; Jules Hirsch, M.D.,
Rockefeller University; James D. Kenney, M.D.,
School of Medicine; Gerhard Levy, Pharm.D.,
State University of N.Y. at Buffalo; Gerald L. Mandell, M.D.,
University of Virginia School of Medicine; Hans Meinertz, M.D.,
University Hospital, Copenhagen; Dan M. Roden, M.D.,
Vanderbilt School of Medicine; F. Estelle R. Simons, M.D.,
University of Manitoba
EDITORIAL FELLOWS: Elizabeth Stephens, M.D.,
Oregon Health Sciences University School of Medicine; Arthur M.F. Yee, M.D., Ph.D.,
Cornell University Medical Center
EDITORIAL ADMINISTRATOR: Marianne Aschenbrenner PUBLISHER: Doris Peter, Ph.D.
Founded 1959 by Arthur Kallet and Harold Aaron, M.D. Copyright
2002. (ISSN 1523-2859)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
FEDERAL DRUG TESTS —
Federal drug testing programs require testing all specimens
for marijuana metabolites, cocaine metabolites, opiate metabolites, amphetamines and phen-
cyclidine. Many multidrug screening assays also detect barbiturates and benzodiazepines in
urine. The US Department of Health and Human Services (DHHS) specifies urine testing in
their current Mandatory Guidelines for Federal Workplace Drug Testing Programs, but drafts
of new guidelines include use of hair, sweat and oral fluidThe
DHHS has established specific threshold concentrations for a positive finding in urine for the
These concentrations were chosen for optimal sensitivity and
specificity. The thresholds for other drugs, such as benzodiazepines, vary with the laboratory
The length of time someone will test positive following drug ingestion
depends on the drug, the dose, its elimination half-life, and the source of the specimen.
FEDERALLY MANDATED URINE TESTS FOR DRUGS OF ABUSE
drine, phenylephrine, am-phetamines, dextroamphe-tamine, methamphetamine,selegiline, chlorpromazine,trazodone, bupropion,desipramine, amantadine,ranitidine
pin, fluoroquinolones, pop-py seeds, quinine in tonicwater
1. DHHS proposed new guidelines: 500 ng/ml2. DHHS proposed new guidelines: 150 ng/ml
Blood and breath concentrations of alcohol
correlate more closely than urine
concentrations with central-nervous-system impairment.
False-positive determinations are especially common with amphetamines
second immunoassay to double-check positive results can reduce the number of false posi-
tives. The exact substance present can be determined by confirmation testing.
is converted into several metabolites; among these, ∆-9-tetrahydrocanna-
binol-9-carboxylic acid can be found in urine in high concentrations for the longest duration of
time. Positive tests from passive inhalation of marijuana smoke or from consumption of
hemp-containing foods found in health-food stores (such as nut butters or cold-pressed cook-
has a short half-life (about 1 hour); it is largely metabolized to benzoylecgonine,
which has an elimination half-life of about 7
The Medical Letter • Vol. 44 (Issue 1137) August 19, 2002
immunoassays are standardized to a single benzodiazepine, such as nor-
diazepam (a diazepam metabolite), and cross-reactivity to other benzodiazepines is variable.
If cross-reactivity to a benzodiazepine with a relatively short half-life, such as lorazepam
, and others), is low, and only a small dose of drug was taken, then the duration of a
positive urine finding will be short compared to a longer half-life benzodiazepine with higher
cross-reactivity, such as diazepam (Valium
, and others).
immunoassays are highly sensitive for compounds showing structural similarity
to morphine, such as codeine, 6-acetylmorphine, and dihydrocodeine, but less sensitive to
more structurally dissimilar opioids such as oxycodone (Oxycontin
, and others) or meperidine
The reliability of tests for drugs of abuse depends on the timing and the
assay. Use of confirmatory tests can reduce the number of false-positive results. Assays of
hair can detect drugs used weeks before. Testing saliva, sweat and hair for abused drugs may
circumvent the tampering that has weakened the reliability of urine specimens, but none of
these sources are standardized as well as urine.
NEOTAME — A NEW ARTIFICIAL SWEETENER
− NutraSweet Co.), an analog of aspartame (NutraSweet
, and others),
has been approved by the FDA for use as a nonnutritive sweetener and "flavor enhancer" in
foods and beverages. Other non-caloric sweeteners available in the US include saccharin
, and others), acesulfame potassium (Sunette
− Medical Letter, 1988; 30:116)and sucralose (Splenda
− Medical Letter, 1998; 40:67). Neotame was approved for use in Aus-tralia and New Zealand in 2001.
Neotame is a water-soluble, non-caloric, white powder synthesized from
aspartame by addition of an N-alkyl group to yield N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester. It is about 7,000 to 13,000 times sweeter than table sugar and
30-60 times sweeter than aspartame, making it the sweetest artificial sweetener available.
Neotame is reported to have a "clean" sweet taste, similar to aspartame, without the markedly
bitter, metallic aftertaste often associated with saccharin
The new sweetener can also be advertised as a flavor enhancer because, in sub-
sweetening doses, it increases the perception of flavors (such as strawberry), presumably by
altering taste rather than any neural mechanism.
About 50% of ingested neotame is absorbed from the GI tract. It
has a serum half-life of about 2 hours, is hydrolyzed by tissue and serum esterases to an
aspartyl-phenylalanine derivative, and eliminated in urine and feces (C Nofre and J-M Tinti,
Food Chem 2000; 69:245). The rest of the dose is mostly excreted intact. Only a small
amount of the phenylalanine present in neotame is bioavailable, and these low levels do not
pose a risk to patients with phenylketonuria.
Neotame is more stable than aspartame at high temperatures and neu-
tral pH, making it suitable for use in some baked goods and hot beverages. The specification
of "some" baked goods is not due to limitations on the stability of the sweetener, but rather to
the use of sugar in some baked goods as a bulking agent. In clinical studies, neotame has
had no effect on plasma glucose and insulin concentrations and can be used by patients with
The Medical Letter • Vol. 44 (Issue 1137) August 19, 2002
diabetes. Animal experiments suggest that neotame, like other non-sugar sweeteners, does
not contribute to development of dental caries.
Approval of neotame was based on the results of 113 unpublished studies in
both animals and humans presented to the FDA (Fed Reg 2002; 67:45300). The animal studies
used doses up to 1000 times higher than the currently approved daily dose and assessed the
effects of both short-term and chronic use.
A case-control study in rats found that the
offspring of rats fed neotame 1000 mg/kg daily had reduced motor activity and ability to swim
through a maze; the offspring of rats fed 100 mg/kg and 300 mg/kg daily were normal. Rever-
sible increases in serum alkaline phosphatase developed in dogs fed more than 60 mg/kg of
neotame daily for 52 weeks, but histopathological studies of the liver found no abnormalities.
Two rodent studies found a decrease in total body weight gain that appeared to be unrelated
to food intake. A 104-week study in rats found no evidence of neotame-induced neoplasia at
doses up to 1000 mg/kg daily. In human studies, neotame dosages of up to about 90-100 mg
daily for 13 weeks were not associated with any clinical or laboratory abnormalities.
Based on animal safety data, the FDA has recommended an acceptable daily
total neotame intake of 18 mg/day. One tabletop packet would contain about 0.9 mg of neo-
tame. Because of its ability to enhance flavors, it is likely that small amounts of neotame will
be blended with other sweeteners in food and beverages.
Neotame is a non-caloric sweetener that is more heat-stable than aspar-
tame, permitting use in cooked foods, and as a tabletop sweetener. Neotame is not yet used
commercially in the US, and its range of uses remains to be defined. The drug’s long-term
safety in humans is unknown, but it appears to be safe for patients with phenylketonuria.
A NEW PUBLICATION:
TREATMENT GUIDELINES FROM THE MEDICAL LETTER
Beginning September 1, 2002, The Medical Letter
will launch a new publication called
Treatment Guidelines from The Medical Letter
. All of our subscribers will receive a free copy
of the first issue, which will be on Drugs for Diabetes.
The new monthly publication will have something old, something new and something
blue. The subject matter will be similar to the summary articles on drug classes that we have
published in The Medical Letter
from time to time and in our Drugs of Choice
main reason for the new publication is our wish to offer these summary articles on a regular
basis, without having to push aside time-sensitive articles on individual new drugs. Most of
the issues will be 6 or 8 pages long. What will be new is the format, which will be two
columns per page, and the use of color (blue). We hope you like it.
THE MEDICAL LETTER
• A NONPROFIT ORGANIZATION
Copyright and Disclaimer:
No part of the material may be reproduced
or transmitted by any process in whole or in part without prior permis-
sion in writing. The editors and publisher do not warrant that all the
residents, and fellows in US and Canada.
material in this publication is accurate and complete in every respect.
Special fees for bulk subscriptions. Special
The editors and publisher shall not be held responsible for any dam-
classroom rates are available. Back issues
age resulting from any error, inaccuracy or omission.
are $5 each. Major credit cards accepted.
: To reproduce any portion of this issue, please write or fax
E-mail: [email protected]
your request, or e-mail to [email protected]
The Medical Letter • Vol. 44 (Issue 1137) August 19, 2002
bijsluiter gen geeft. Maar ook de angst voor bijwerkin • Stel uw vraag aan de webapotheker op gen is een belangrijke reden om te stoppen. www.apotheek.nl . U krijgt binnen enkele daBedenk echter dat iedereen anders op medigen per email antwoord van een apotheker. cijnen reageert, en dat u van een flink deel van • Gebruikt u medicijnen vanwege een bepaal de bijwerki
ENFERMEDAD DE PARKINSON Guía terapéutica de la Sociedad Catalana de Neurología Coordinador : Dr. Jaume Kulisevsky Bojarski, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau Consejo Asesor : Dr. Miguel Agular Barberá, Servicio de Neurología, Hospital Mutua de Tarrassa Dra. Matilde Calopa Garriga, Servicio de Neurología, Hospital de Bellvitge Dra. María José Ma